Chain of Identity and Chain of Custody in personalized therapies -- core differences from traditional pharma
by Heidi Hagen | October 30, 2019
In pharmaceutical manufacturing, Chain of Identity and Chain of Custody may not be new -- but in advanced therapy manufacturing, they take on a whole new significance. Why? Because in personalized therapies, a person is a key part of the process.
by Vineti | October 23, 2019
Mike Pellini, M.D., is a member of Vineti’s Board of Directors, a Managing Partner at Section 32, and the former CEO and Chairman of cancer genomics trailblazer Foundation Medicine. He is a leading voice on how the life sciences will continue to…
by Heidi Hagen | October 17, 2019
Why is the distinction between the supply chain and value chain important in cell therapies, gene therapies, and personalized cancer vaccines? As it turns out, it all comes back to the patient.
by Heidi Hagen | August 27, 2019
Next month, my colleagues at Vineti and I will be speaking, writing, and presenting on a topic of critical importance to cell and gene therapy -- data management. Why now? Because in advanced therapeutics, data management is patient management. To…
by Amy DuRoss | July 30, 2019
While every day we seek to bring kaizen to cell and gene therapy, we still have an important first step to accomplish as an industry (as we all know) -- standardization. Without standardization, we can’t optimize or achieve truly “lean”…